<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01076179</url>
  </required_header>
  <id_info>
    <org_study_id>P11-021</org_study_id>
    <nct_id>NCT01076179</nct_id>
  </id_info>
  <brief_title>Kaletra in Combination With Antiretroviral Agents</brief_title>
  <acronym>PROTEKT</acronym>
  <official_title>KALETRA in Combination With New Substances (PROTEKT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie (prior sponsor, Abbott)</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the tolerability of Kaletra (lopinavir/ritonavir)
      in combination with new substances such as integrase inhibitors (INIs), C-C chemokine
      receptor type 5 (CCR5) antagonists, and new non-nucleoside reverse transcriptase inhibitors
      (NNRTIs), as there are many reasons (intolerability, complex resistant patterns or even
      personal reasons) which may result in a change from the daily clinical routine and lead to
      the use of a newly approved antiretroviral agent in combination with Kaletra.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study was designed as a non-interventional observational study. Kaletra was prescribed
      in the usual manner in accordance with the terms of the local market authorization with
      regards to dose, population and indication as well as local guidelines.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence of Adverse Events (Weeks 0-144), Per Event</measure>
    <time_frame>Weeks 0 to 144</time_frame>
    <description>Percentage of overall number of adverse events experienced during Weeks 0-144 by adverse event type. Doctors asked participants for adverse events, grouped them into categories given in the electronic case report form (eCRF). The list of adverse events included in the eCRF were hypertriglyceridemia, hypercholesterolemia, low high density lipoprotein (HDL) cholesterol, high low density lipoprotein (LDL) cholesterol, hyperglycemia, hyperbilirubinemia, elevated aspartate aminotransferase (AST), elevated alanine aminotransferase (ALT), elevated gamma glutamyl transferase (γGT), elevated alkaline phosphatase, stomatitis, nausea, vomiting, diarrhea, abdominal pain, mood disorder, neurocerebellar disorder, headache, fatigue, fever, other (listed as 'not specified').</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Prevalence of Adverse Events (Weeks 0-144), Per Participant</measure>
    <time_frame>Weeks 0 to 144</time_frame>
    <description>Percentage of participants who experienced at least 1 adverse event during Weeks 0-144 by adverse event type. Doctors asked participants for adverse events, grouped them into categories given in the eCRF. The list of adverse events included in the eCRF were hypertriglyceridemia, hypercholesterolemia, low HDL cholesterol, high LDL cholesterol, hyperglycemia, hyperbilirubinemia, elevated AST, elevated ALT, elevated γGT, elevated alkaline phosphatase, stomatitis, nausea, vomiting, diarrhea, abdominal pain, mood disorder, neurocerebellar disorder, headache, fatigue, fever, other (listed as 'not specified').</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Absolute Cluster of Differentiation 4 (CD4) Cell Count</measure>
    <time_frame>Baseline (Week 0) to Week 144</time_frame>
    <description>Changes in participants' CD4 cell counts were assessed by measuring the change from Baseline in the number of CD4 cells at scheduled visits planned as part of routine care.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Absolute CD4 Cell Count Increases From Baseline of ≥ 100 Cells/μL at All Time Points, Modified Intent-to-Treat Analysis</measure>
    <time_frame>Baseline (Week 0) to Week 144</time_frame>
    <description>Changes in participants' CD4 cell counts were assessed by measuring the number of CD4 cells at scheduled visits planned as part of routine care.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Absolute CD4 Cell Count Increases From Baseline of ≥ 100 Cells/μL at All Time Points, As Treated Analysis</measure>
    <time_frame>Baseline (Week 0) to Week 144</time_frame>
    <description>Changes in participants' CD4 cell counts were assessed by measuring the number of CD4 cells at scheduled visits planned as part of routine care.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to CD4 Cell Count Increase From Baseline of ≥ 100/ Cells/μL</measure>
    <time_frame>From Week 0 to Week 144</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Lopinavir (LPV) Resistance at Baseline</measure>
    <time_frame>Baseline (Week 0)</time_frame>
    <description>Characterization of baseline resistance and development of resistance using the interpretation system HIV-Genotypic Resistance-Algorithm Deutschland (GRADE; available at www.hiv-grade.de.
Genotypic interpretation was performed using the HIV-GRADE algorithm updated in December 2015). &quot;Susceptible&quot; indicates full susceptibility of a virus to a certain drug without any limitations in terms of resistance. &quot;Partial&quot; resistance is indicated if severe limitations in susceptibility have to be expected and the drug can not count for a fully active drug any more. However, these drugs can still be very useful in situations with generally limited options (salvage). &quot;Resistant&quot; indicates that high level drug resistance has to be expected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With LPV Resistance During Follow-Up</measure>
    <time_frame>up to Week 144</time_frame>
    <description>Characterization of baseline resistance and development of resistance using the interpretation system HIV-GRADE (available at www.hiv-grade.de. Genotypic interpretation was performed using the HIV-GRADE algorithm updated in December 2015). &quot;Susceptible&quot; indicates full susceptibility of a virus to a certain drug without any limitations in terms of resistance. &quot;Partial&quot; resistance is indicated if severe limitations in susceptibility have to be expected and the drug can not count for a fully active drug any more. However, these drugs can still be very useful in situations with generally limited options (salvage). &quot;Resistant&quot; indicates that high level drug resistance has to be expected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Protease Inhibitor (PI) Resistance at Baseline</measure>
    <time_frame>Baseline (Week 0)</time_frame>
    <description>Characterization of baseline resistance and development of resistance using the interpretation system HIV-Genotypic Resistance-Algorithm Deutschland (GRADE; available at www.hiv-grade.de.
Genotypic interpretation was performed using the HIV-GRADE algorithm updated in December 2015). &quot;Susceptible&quot; indicates full susceptibility of a virus to a certain drug without any limitations in terms of resistance. &quot;Partial&quot; resistance is indicated if severe limitations in susceptibility have to be expected and the drug can not count for a fully active drug any more. However, these drugs can still be very useful in situations with generally limited options (salvage). &quot;Resistant&quot; indicates that high level drug resistance has to be expected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With PI Resistance During Follow-Up</measure>
    <time_frame>Up to Week 144</time_frame>
    <description>Characterization of baseline resistance and development of resistance using the interpretation system HIV-GRADE (available at www.hiv-grade.de. Genotypic interpretation was performed using the HIV-GRADE algorithm updated in December 2015). &quot;Susceptible&quot; indicates full susceptibility of a virus to a certain drug without any limitations in terms of resistance. &quot;Partial&quot; resistance is indicated if severe limitations in susceptibility have to be expected and the drug can not count for a fully active drug any more. However, these drugs can still be very useful in situations with generally limited options (salvage). &quot;Resistant&quot; indicates that high level drug resistance has to be expected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With INI Resistance at Baseline</measure>
    <time_frame>Baseline (Week 0)</time_frame>
    <description>Characterization of baseline resistance and development of resistance using the interpretation system HIV-GRADE (available at www.hiv-grade.de. Genotypic interpretation was performed using the HIV-GRADE algorithm updated in December 2015). &quot;Susceptible&quot; indicates full susceptibility of a virus to a certain drug without any limitations in terms of resistance. &quot;Partial&quot; resistance is indicated if severe limitations in susceptibility have to be expected and the drug can not count for a fully active drug any more. However, these drugs can still be very useful in situations with generally limited options (salvage). &quot;Resistant&quot; indicates that high level drug resistance has to be expected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With INI Resistance During Follow-Up</measure>
    <time_frame>up to Week 144</time_frame>
    <description>Characterization of baseline resistance and development of resistance using the interpretation system HIV-GRADE (available at www.hiv-grade.de. Genotypic interpretation was performed using the HIV-GRADE algorithm updated in December 2015). &quot;Susceptible&quot; indicates full susceptibility of a virus to a certain drug without any limitations in terms of resistance. &quot;Partial&quot; resistance is indicated if severe limitations in susceptibility have to be expected and the drug can not count for a fully active drug any more. However, these drugs can still be very useful in situations with generally limited options (salvage). &quot;Resistant&quot; indicates that high level drug resistance has to be expected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With NNRTI Resistance at Baseline</measure>
    <time_frame>Baseline (Week 0)</time_frame>
    <description>Characterization of baseline resistance and development of resistance using the interpretation system HIV-GRADE (available at www.hiv-grade.de. Genotypic interpretation was performed using the HIV-GRADE algorithm updated in December 2015). &quot;Susceptible&quot; indicates full susceptibility of a virus to a certain drug without any limitations in terms of resistance. &quot;Partial&quot; resistance is indicated if severe limitations in susceptibility have to be expected and the drug can not count for a fully active drug any more. However, these drugs can still be very useful in situations with generally limited options (salvage). &quot;Resistant&quot; indicates that high level drug resistance has to be expected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With NNRTI Resistance During Follow-Up</measure>
    <time_frame>up to Week 144</time_frame>
    <description>Characterization of baseline resistance and development of resistance using the interpretation system HIV-GRADE (available at www.hiv-grade.de. Genotypic interpretation was performed using the HIV-GRADE algorithm updated in December 2015). &quot;Susceptible&quot; indicates full susceptibility of a virus to a certain drug without any limitations in terms of resistance. &quot;Partial&quot; resistance is indicated if severe limitations in susceptibility have to be expected and the drug can not count for a fully active drug any more. However, these drugs can still be very useful in situations with generally limited options (salvage). &quot;Resistant&quot; indicates that high level drug resistance has to be expected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Nucleoside Analog Reverse-Transcriptase Inhibitor (NRTI) Resistance at Baseline</measure>
    <time_frame>Baseline (Week 0)</time_frame>
    <description>Characterization of baseline resistance and development of resistance using the interpretation system HIV-GRADE (available at www.hiv-grade.de. Genotypic interpretation was performed using the HIV-GRADE algorithm updated in December 2015). &quot;Susceptible&quot; indicates full susceptibility of a virus to a certain drug without any limitations in terms of resistance. &quot;Partial&quot; resistance is indicated if severe limitations in susceptibility have to be expected and the drug can not count for a fully active drug any more. However, these drugs can still be very useful in situations with generally limited options (salvage). &quot;Resistant&quot; indicates that high level drug resistance has to be expected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With NRTI Resistance During Follow-Up</measure>
    <time_frame>up to Week 144</time_frame>
    <description>Characterization of baseline resistance and development of resistance using the interpretation system HIV-GRADE (available at www.hiv-grade.de. Genotypic interpretation was performed using the HIV-GRADE algorithm updated in December 2015). &quot;Susceptible&quot; indicates full susceptibility of a virus to a certain drug without any limitations in terms of resistance. &quot;Partial&quot; resistance is indicated if severe limitations in susceptibility have to be expected and the drug can not count for a fully active drug any more. However, these drugs can still be very useful in situations with generally limited options (salvage). &quot;Resistant&quot; indicates that high level drug resistance has to be expected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With HIV-1 Coreceptor Tropism at Baseline</measure>
    <time_frame>Baseline (Week 0)</time_frame>
    <description>Participants with CCR5 tropic virus, CXC motif chemokine receptor 4 (CRCX4) tropic virus, or dual/mixed tropic virus at Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With HIV-1 Coreceptor Tropism During Follow-up</measure>
    <time_frame>up to Week 144</time_frame>
    <description>Participants with CCR5 tropic virus, CXC motif chemokine receptor 4 (CRCX4) tropic virus, or dual/mixed tropic virus at Follow-up.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change From Baseline in HIV-1 Ribonucleic Acid (RNA) Viral Load</measure>
    <time_frame>Baseline (Week 0) to Week 144</time_frame>
    <description>Changes in participants' HIV-1 RNA viral load were assessed by measuring the change from Baseline at scheduled visits planned as part of routine care.</description>
  </other_outcome>
  <other_outcome>
    <measure>Time to Virologic Failure</measure>
    <time_frame>Baseline (Week 0) to Week 144</time_frame>
    <description>Time to virologic failure was defined by the earliest occurrence of:
HIV-1 RNA &gt; 400 copies/mL confirmed on 2 consecutive occasions after achieving at least 1 HIV-1 RNA &lt; 50 copies/mL,
HIV-1 RNA &gt; 400 copies/mL at the final on-study visit if the participant had previously experienced at least 1 HIV-1 RNA &lt; 50 copies/mL but subsequently did not have HIV-1 RNA &gt; 400 copies/mL on 2 consecutive occasions, or
Day 1 if the participant never achieved HIV-1 RNA &lt; 50 copies/mL during study participation.
A participant who prematurely discontinued study drug with HIV-1 RNA &lt; 50 copies/mL was censored from analysis at the time of discontinuation provided that he/she did not previously experience either (a), (b) or (c).</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">502</enrollment>
  <condition>Human Immunodeficiency Virus</condition>
  <arm_group>
    <arm_group_label>Human Immunodeficiency Virus (HIV)-Infected Participants</arm_group_label>
    <description>HIV-infected participants on Kaletra and INIs or NNRTIs or CCR5 antagonists</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Community sample: HIV-positive patients
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients ≥ 18years of age

          -  Written informed consent (authorization to the investigator to use and/or disclose
             personal and/or health data before entry into the KALETRA® post marketing
             observational study)

          -  HIV-1 infection

          -  Patients treated with KALETRA®, independent from their participation in this study

          -  Patients treated with novel antiretroviral therapy (for at least 8 weeks according to
             the study amendment), independent from their participation in this study

        Exclusion Criteria:

          -  Hypersensitivity against Kaletra or other ingredients or INIs or NNRTIs or CCR5
             antagonists

          -  Severe liver insufficiency

          -  No concommitant astemizole, terfenadine, oral midazolam, triazolam, cisapride,
             pimozide, amiodarone, ergotamine, dihydroergotamine, ergometrine, methylergometrine,
             vardenafil and/or St. John's wort
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bianca Wittig, MD</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie Deutschland GmbH &amp; Co. KG, Medical Department</affiliation>
  </overall_official>
  <removed_countries>
    <country>Germany</country>
  </removed_countries>
  <link>
    <url>http://rxabbvie.com</url>
  </link>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 24, 2010</study_first_submitted>
  <study_first_submitted_qc>February 24, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 26, 2010</study_first_posted>
  <results_first_submitted>January 18, 2017</results_first_submitted>
  <results_first_submitted_qc>May 18, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">May 19, 2017</results_first_posted>
  <last_update_submitted>May 18, 2017</last_update_submitted>
  <last_update_submitted_qc>May 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Infection</keyword>
  <keyword>Rilpivirine</keyword>
  <keyword>CCR5 antagonists</keyword>
  <keyword>Etravirine</keyword>
  <keyword>Human Immunodeficiency Virus</keyword>
  <keyword>Maraviroc</keyword>
  <keyword>Safety and efficacy</keyword>
  <keyword>Non nucleoside reverse transcriptase inhibitors (NNRTIs)</keyword>
  <keyword>Integrase inhibitors</keyword>
  <keyword>Raltegravir</keyword>
  <keyword>Kaletra</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lopinavir</mesh_term>
    <mesh_term>Anti-Retroviral Agents</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>HIV-infected Participants</title>
          <description>Human immunodeficiency virus (HIV)-infected participants on Kaletra and integrase inhibitors (INIs) or non nucleoside reverse transcriptase inhibitors NNRTIs) or C-C chemokine receptor type 5 (CCR5) antagonists</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="502"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="501"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>HIV-infected Participants</title>
          <description>HIV-infected participants on Kaletra and INIs or NNRTIs or CCR5 antagonists</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="501"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.4" spread="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="431"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Prevalence of Adverse Events (Weeks 0-144), Per Event</title>
        <description>Percentage of overall number of adverse events experienced during Weeks 0-144 by adverse event type. Doctors asked participants for adverse events, grouped them into categories given in the electronic case report form (eCRF). The list of adverse events included in the eCRF were hypertriglyceridemia, hypercholesterolemia, low high density lipoprotein (HDL) cholesterol, high low density lipoprotein (LDL) cholesterol, hyperglycemia, hyperbilirubinemia, elevated aspartate aminotransferase (AST), elevated alanine aminotransferase (ALT), elevated gamma glutamyl transferase (γGT), elevated alkaline phosphatase, stomatitis, nausea, vomiting, diarrhea, abdominal pain, mood disorder, neurocerebellar disorder, headache, fatigue, fever, other (listed as 'not specified').</description>
        <time_frame>Weeks 0 to 144</time_frame>
        <group_list>
          <group group_id="O1">
            <title>HIV-infected Participants</title>
            <description>HIV-infected participants on Kaletra and INIs or NNRTIs or CCR5 antagonists</description>
          </group>
        </group_list>
        <measure>
          <title>Prevalence of Adverse Events (Weeks 0-144), Per Event</title>
          <description>Percentage of overall number of adverse events experienced during Weeks 0-144 by adverse event type. Doctors asked participants for adverse events, grouped them into categories given in the electronic case report form (eCRF). The list of adverse events included in the eCRF were hypertriglyceridemia, hypercholesterolemia, low high density lipoprotein (HDL) cholesterol, high low density lipoprotein (LDL) cholesterol, hyperglycemia, hyperbilirubinemia, elevated aspartate aminotransferase (AST), elevated alanine aminotransferase (ALT), elevated gamma glutamyl transferase (γGT), elevated alkaline phosphatase, stomatitis, nausea, vomiting, diarrhea, abdominal pain, mood disorder, neurocerebellar disorder, headache, fatigue, fever, other (listed as 'not specified').</description>
          <units>percentage of adverse events</units>
          <param>Number</param>
          <units_analyzed>Adverse Events</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="501"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Adverse Events</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3450"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hypertriglyceridemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypercholesterolemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low HDL Cholesterol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High LDL Cholesterol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hyperglycemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hyperbilirubinemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Elevated AST</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Elevated ALT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Elevated γGT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Elevated Alkaline Phosphatase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stomatitis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abdominal Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mood Disorder</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neurocerebellar Disorder</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Specified</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Prevalence of Adverse Events (Weeks 0-144), Per Participant</title>
        <description>Percentage of participants who experienced at least 1 adverse event during Weeks 0-144 by adverse event type. Doctors asked participants for adverse events, grouped them into categories given in the eCRF. The list of adverse events included in the eCRF were hypertriglyceridemia, hypercholesterolemia, low HDL cholesterol, high LDL cholesterol, hyperglycemia, hyperbilirubinemia, elevated AST, elevated ALT, elevated γGT, elevated alkaline phosphatase, stomatitis, nausea, vomiting, diarrhea, abdominal pain, mood disorder, neurocerebellar disorder, headache, fatigue, fever, other (listed as 'not specified').</description>
        <time_frame>Weeks 0 to 144</time_frame>
        <group_list>
          <group group_id="O1">
            <title>HIV-infected Participants</title>
            <description>HIV-infected participants on Kaletra and INIs or NNRTIs or CCR5 antagonists</description>
          </group>
        </group_list>
        <measure>
          <title>Prevalence of Adverse Events (Weeks 0-144), Per Participant</title>
          <description>Percentage of participants who experienced at least 1 adverse event during Weeks 0-144 by adverse event type. Doctors asked participants for adverse events, grouped them into categories given in the eCRF. The list of adverse events included in the eCRF were hypertriglyceridemia, hypercholesterolemia, low HDL cholesterol, high LDL cholesterol, hyperglycemia, hyperbilirubinemia, elevated AST, elevated ALT, elevated γGT, elevated alkaline phosphatase, stomatitis, nausea, vomiting, diarrhea, abdominal pain, mood disorder, neurocerebellar disorder, headache, fatigue, fever, other (listed as 'not specified').</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="501"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hypertriglyceridemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypercholesterolemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low HDL Cholesterol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High LDL Cholesterol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hyperglycemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hyperbilirubinemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Elevated AST</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Elevated ALT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Elevated γGT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Elevated Alkaline Phosphatase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stomatitis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abdominal Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mood Disorder</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neurocerebellar Disorder</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Specified</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Absolute Cluster of Differentiation 4 (CD4) Cell Count</title>
        <description>Changes in participants' CD4 cell counts were assessed by measuring the change from Baseline in the number of CD4 cells at scheduled visits planned as part of routine care.</description>
        <time_frame>Baseline (Week 0) to Week 144</time_frame>
        <population>Participants with an assessment at Baseline. Number analyzed=participants with an assessment at given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>HIV-infected Participants</title>
            <description>HIV-infected participants on Kaletra and INIs or NNRTIs or CCR5 antagonists</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Absolute Cluster of Differentiation 4 (CD4) Cell Count</title>
          <description>Changes in participants' CD4 cell counts were assessed by measuring the change from Baseline in the number of CD4 cells at scheduled visits planned as part of routine care.</description>
          <population>Participants with an assessment at Baseline. Number analyzed=participants with an assessment at given time point.</population>
          <units>cells/μL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="500"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="369"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.0" spread="161.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="400"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.6" spread="148.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="414"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.8" spread="195.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="363"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.8" spread="214.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="344"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="107.4" spread="213.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="315"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="131.0" spread="247.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 72</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="300"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="125.3" spread="216.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 84</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="266"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="142.8" spread="223.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 96</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="265"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="143.3" spread="207.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 108</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="233"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="155.3" spread="219.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 120</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="219"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="170.9" spread="233.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 132</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="212"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="180.3" spread="243.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 144</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="212"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="190.0" spread="252.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving Absolute CD4 Cell Count Increases From Baseline of ≥ 100 Cells/μL at All Time Points, Modified Intent-to-Treat Analysis</title>
        <description>Changes in participants' CD4 cell counts were assessed by measuring the number of CD4 cells at scheduled visits planned as part of routine care.</description>
        <time_frame>Baseline (Week 0) to Week 144</time_frame>
        <population>Modified 'intent-to-treat' analysis: missing values were replaced by the last observed value of that variable (last observation carried forward method).</population>
        <group_list>
          <group group_id="O1">
            <title>HIV-infected Participants</title>
            <description>HIV-infected participants on Kaletra and INIs or NNRTIs or CCR5 antagonists</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Absolute CD4 Cell Count Increases From Baseline of ≥ 100 Cells/μL at All Time Points, Modified Intent-to-Treat Analysis</title>
          <description>Changes in participants' CD4 cell counts were assessed by measuring the number of CD4 cells at scheduled visits planned as part of routine care.</description>
          <population>Modified 'intent-to-treat' analysis: missing values were replaced by the last observed value of that variable (last observation carried forward method).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="501"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 84</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 108</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 120</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 132</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 144</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving Absolute CD4 Cell Count Increases From Baseline of ≥ 100 Cells/μL at All Time Points, As Treated Analysis</title>
        <description>Changes in participants' CD4 cell counts were assessed by measuring the number of CD4 cells at scheduled visits planned as part of routine care.</description>
        <time_frame>Baseline (Week 0) to Week 144</time_frame>
        <population>'As treated' analyses: participants with an assessment, missing data excluded. Number analyzed=participants with an assessment at given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>HIV-infected Participants</title>
            <description>HIV-infected participants on Kaletra and INIs or NNRTIs or CCR5 antagonists</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Absolute CD4 Cell Count Increases From Baseline of ≥ 100 Cells/μL at All Time Points, As Treated Analysis</title>
          <description>Changes in participants' CD4 cell counts were assessed by measuring the number of CD4 cells at scheduled visits planned as part of routine care.</description>
          <population>'As treated' analyses: participants with an assessment, missing data excluded. Number analyzed=participants with an assessment at given time point.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="501"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="369"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="400"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="414"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="363"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="344"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="315"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="300"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 84</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="266"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="265"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 108</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="233"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 120</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="219"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 132</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="212"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 144</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="212"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to CD4 Cell Count Increase From Baseline of ≥ 100/ Cells/μL</title>
        <time_frame>From Week 0 to Week 144</time_frame>
        <population>Participants with an assessment</population>
        <group_list>
          <group group_id="O1">
            <title>HIV-infected Participants</title>
            <description>HIV-infected participants on Kaletra and INIs or NNRTIs or CCR5 antagonists</description>
          </group>
        </group_list>
        <measure>
          <title>Time to CD4 Cell Count Increase From Baseline of ≥ 100/ Cells/μL</title>
          <population>Participants with an assessment</population>
          <units>weeks</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="498"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.1" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Lopinavir (LPV) Resistance at Baseline</title>
        <description>Characterization of baseline resistance and development of resistance using the interpretation system HIV-Genotypic Resistance-Algorithm Deutschland (GRADE; available at www.hiv-grade.de.
Genotypic interpretation was performed using the HIV-GRADE algorithm updated in December 2015). &quot;Susceptible&quot; indicates full susceptibility of a virus to a certain drug without any limitations in terms of resistance. &quot;Partial&quot; resistance is indicated if severe limitations in susceptibility have to be expected and the drug can not count for a fully active drug any more. However, these drugs can still be very useful in situations with generally limited options (salvage). &quot;Resistant&quot; indicates that high level drug resistance has to be expected.</description>
        <time_frame>Baseline (Week 0)</time_frame>
        <population>Participants with an assessment at Baseline</population>
        <group_list>
          <group group_id="O1">
            <title>HIV-infected Participants</title>
            <description>HIV-infected participants on Kaletra and INIs or NNRTIs or CCR5 antagonists</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Lopinavir (LPV) Resistance at Baseline</title>
          <description>Characterization of baseline resistance and development of resistance using the interpretation system HIV-Genotypic Resistance-Algorithm Deutschland (GRADE; available at www.hiv-grade.de.
Genotypic interpretation was performed using the HIV-GRADE algorithm updated in December 2015). &quot;Susceptible&quot; indicates full susceptibility of a virus to a certain drug without any limitations in terms of resistance. &quot;Partial&quot; resistance is indicated if severe limitations in susceptibility have to be expected and the drug can not count for a fully active drug any more. However, these drugs can still be very useful in situations with generally limited options (salvage). &quot;Resistant&quot; indicates that high level drug resistance has to be expected.</description>
          <population>Participants with an assessment at Baseline</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="159"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Susceptible</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="155"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Resistance/Partial Resistance</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With LPV Resistance During Follow-Up</title>
        <description>Characterization of baseline resistance and development of resistance using the interpretation system HIV-GRADE (available at www.hiv-grade.de. Genotypic interpretation was performed using the HIV-GRADE algorithm updated in December 2015). &quot;Susceptible&quot; indicates full susceptibility of a virus to a certain drug without any limitations in terms of resistance. &quot;Partial&quot; resistance is indicated if severe limitations in susceptibility have to be expected and the drug can not count for a fully active drug any more. However, these drugs can still be very useful in situations with generally limited options (salvage). &quot;Resistant&quot; indicates that high level drug resistance has to be expected.</description>
        <time_frame>up to Week 144</time_frame>
        <population>Participants with an assessment during follow-up; since this was an observational study, resistance testing was performed at the discretion of the treating physician.</population>
        <group_list>
          <group group_id="O1">
            <title>HIV-infected Participants</title>
            <description>HIV-infected participants on Kaletra and INIs or NNRTIs or CCR5 antagonists</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With LPV Resistance During Follow-Up</title>
          <description>Characterization of baseline resistance and development of resistance using the interpretation system HIV-GRADE (available at www.hiv-grade.de. Genotypic interpretation was performed using the HIV-GRADE algorithm updated in December 2015). &quot;Susceptible&quot; indicates full susceptibility of a virus to a certain drug without any limitations in terms of resistance. &quot;Partial&quot; resistance is indicated if severe limitations in susceptibility have to be expected and the drug can not count for a fully active drug any more. However, these drugs can still be very useful in situations with generally limited options (salvage). &quot;Resistant&quot; indicates that high level drug resistance has to be expected.</description>
          <population>Participants with an assessment during follow-up; since this was an observational study, resistance testing was performed at the discretion of the treating physician.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Susceptible</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Resistance/Partial Resistance</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Protease Inhibitor (PI) Resistance at Baseline</title>
        <description>Characterization of baseline resistance and development of resistance using the interpretation system HIV-Genotypic Resistance-Algorithm Deutschland (GRADE; available at www.hiv-grade.de.
Genotypic interpretation was performed using the HIV-GRADE algorithm updated in December 2015). &quot;Susceptible&quot; indicates full susceptibility of a virus to a certain drug without any limitations in terms of resistance. &quot;Partial&quot; resistance is indicated if severe limitations in susceptibility have to be expected and the drug can not count for a fully active drug any more. However, these drugs can still be very useful in situations with generally limited options (salvage). &quot;Resistant&quot; indicates that high level drug resistance has to be expected.</description>
        <time_frame>Baseline (Week 0)</time_frame>
        <population>Participants with an assessment at Baseline</population>
        <group_list>
          <group group_id="O1">
            <title>HIV-infected Participants</title>
            <description>HIV-infected participants on Kaletra and INIs or NNRTIs or CCR5 antagonists</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Protease Inhibitor (PI) Resistance at Baseline</title>
          <description>Characterization of baseline resistance and development of resistance using the interpretation system HIV-Genotypic Resistance-Algorithm Deutschland (GRADE; available at www.hiv-grade.de.
Genotypic interpretation was performed using the HIV-GRADE algorithm updated in December 2015). &quot;Susceptible&quot; indicates full susceptibility of a virus to a certain drug without any limitations in terms of resistance. &quot;Partial&quot; resistance is indicated if severe limitations in susceptibility have to be expected and the drug can not count for a fully active drug any more. However, these drugs can still be very useful in situations with generally limited options (salvage). &quot;Resistant&quot; indicates that high level drug resistance has to be expected.</description>
          <population>Participants with an assessment at Baseline</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="159"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Susceptible</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="142"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Resistance/Partial Resistance</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With PI Resistance During Follow-Up</title>
        <description>Characterization of baseline resistance and development of resistance using the interpretation system HIV-GRADE (available at www.hiv-grade.de. Genotypic interpretation was performed using the HIV-GRADE algorithm updated in December 2015). &quot;Susceptible&quot; indicates full susceptibility of a virus to a certain drug without any limitations in terms of resistance. &quot;Partial&quot; resistance is indicated if severe limitations in susceptibility have to be expected and the drug can not count for a fully active drug any more. However, these drugs can still be very useful in situations with generally limited options (salvage). &quot;Resistant&quot; indicates that high level drug resistance has to be expected.</description>
        <time_frame>Up to Week 144</time_frame>
        <population>Participants with an assessment during follow-up; since this was an observational study, resistance testing was performed at the discretion of the treating physician.</population>
        <group_list>
          <group group_id="O1">
            <title>HIV-infected Participants</title>
            <description>HIV-infected participants on Kaletra and INIs or NNRTIs or CCR5 antagonists</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With PI Resistance During Follow-Up</title>
          <description>Characterization of baseline resistance and development of resistance using the interpretation system HIV-GRADE (available at www.hiv-grade.de. Genotypic interpretation was performed using the HIV-GRADE algorithm updated in December 2015). &quot;Susceptible&quot; indicates full susceptibility of a virus to a certain drug without any limitations in terms of resistance. &quot;Partial&quot; resistance is indicated if severe limitations in susceptibility have to be expected and the drug can not count for a fully active drug any more. However, these drugs can still be very useful in situations with generally limited options (salvage). &quot;Resistant&quot; indicates that high level drug resistance has to be expected.</description>
          <population>Participants with an assessment during follow-up; since this was an observational study, resistance testing was performed at the discretion of the treating physician.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Susceptible</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Resistance/Partial Resistance</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With INI Resistance at Baseline</title>
        <description>Characterization of baseline resistance and development of resistance using the interpretation system HIV-GRADE (available at www.hiv-grade.de. Genotypic interpretation was performed using the HIV-GRADE algorithm updated in December 2015). &quot;Susceptible&quot; indicates full susceptibility of a virus to a certain drug without any limitations in terms of resistance. &quot;Partial&quot; resistance is indicated if severe limitations in susceptibility have to be expected and the drug can not count for a fully active drug any more. However, these drugs can still be very useful in situations with generally limited options (salvage). &quot;Resistant&quot; indicates that high level drug resistance has to be expected.</description>
        <time_frame>Baseline (Week 0)</time_frame>
        <population>Participants with an assessment at Baseline</population>
        <group_list>
          <group group_id="O1">
            <title>HIV-infected Participants</title>
            <description>HIV-infected participants on Kaletra and INIs or NNRTIs or CCR5 antagonists</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With INI Resistance at Baseline</title>
          <description>Characterization of baseline resistance and development of resistance using the interpretation system HIV-GRADE (available at www.hiv-grade.de. Genotypic interpretation was performed using the HIV-GRADE algorithm updated in December 2015). &quot;Susceptible&quot; indicates full susceptibility of a virus to a certain drug without any limitations in terms of resistance. &quot;Partial&quot; resistance is indicated if severe limitations in susceptibility have to be expected and the drug can not count for a fully active drug any more. However, these drugs can still be very useful in situations with generally limited options (salvage). &quot;Resistant&quot; indicates that high level drug resistance has to be expected.</description>
          <population>Participants with an assessment at Baseline</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Susceptible</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Resistance/Partial Resistance</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With INI Resistance During Follow-Up</title>
        <description>Characterization of baseline resistance and development of resistance using the interpretation system HIV-GRADE (available at www.hiv-grade.de. Genotypic interpretation was performed using the HIV-GRADE algorithm updated in December 2015). &quot;Susceptible&quot; indicates full susceptibility of a virus to a certain drug without any limitations in terms of resistance. &quot;Partial&quot; resistance is indicated if severe limitations in susceptibility have to be expected and the drug can not count for a fully active drug any more. However, these drugs can still be very useful in situations with generally limited options (salvage). &quot;Resistant&quot; indicates that high level drug resistance has to be expected.</description>
        <time_frame>up to Week 144</time_frame>
        <population>Participants with an assessment at follow-up (neither had available Baseline testing); since this was an observational study, resistance testing was performed at the discretion of the treating physician.</population>
        <group_list>
          <group group_id="O1">
            <title>HIV-infected Participants</title>
            <description>HIV-infected participants on Kaletra and INIs or NNRTIs or CCR5 antagonists</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With INI Resistance During Follow-Up</title>
          <description>Characterization of baseline resistance and development of resistance using the interpretation system HIV-GRADE (available at www.hiv-grade.de. Genotypic interpretation was performed using the HIV-GRADE algorithm updated in December 2015). &quot;Susceptible&quot; indicates full susceptibility of a virus to a certain drug without any limitations in terms of resistance. &quot;Partial&quot; resistance is indicated if severe limitations in susceptibility have to be expected and the drug can not count for a fully active drug any more. However, these drugs can still be very useful in situations with generally limited options (salvage). &quot;Resistant&quot; indicates that high level drug resistance has to be expected.</description>
          <population>Participants with an assessment at follow-up (neither had available Baseline testing); since this was an observational study, resistance testing was performed at the discretion of the treating physician.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Susceptible</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Resistance/Partial Resistance</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With NNRTI Resistance at Baseline</title>
        <description>Characterization of baseline resistance and development of resistance using the interpretation system HIV-GRADE (available at www.hiv-grade.de. Genotypic interpretation was performed using the HIV-GRADE algorithm updated in December 2015). &quot;Susceptible&quot; indicates full susceptibility of a virus to a certain drug without any limitations in terms of resistance. &quot;Partial&quot; resistance is indicated if severe limitations in susceptibility have to be expected and the drug can not count for a fully active drug any more. However, these drugs can still be very useful in situations with generally limited options (salvage). &quot;Resistant&quot; indicates that high level drug resistance has to be expected.</description>
        <time_frame>Baseline (Week 0)</time_frame>
        <population>Participants with an assessment at Baseline</population>
        <group_list>
          <group group_id="O1">
            <title>HIV-infected Participants</title>
            <description>HIV-infected participants on Kaletra and INIs or NNRTIs or CCR5 antagonists</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With NNRTI Resistance at Baseline</title>
          <description>Characterization of baseline resistance and development of resistance using the interpretation system HIV-GRADE (available at www.hiv-grade.de. Genotypic interpretation was performed using the HIV-GRADE algorithm updated in December 2015). &quot;Susceptible&quot; indicates full susceptibility of a virus to a certain drug without any limitations in terms of resistance. &quot;Partial&quot; resistance is indicated if severe limitations in susceptibility have to be expected and the drug can not count for a fully active drug any more. However, these drugs can still be very useful in situations with generally limited options (salvage). &quot;Resistant&quot; indicates that high level drug resistance has to be expected.</description>
          <population>Participants with an assessment at Baseline</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="159"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Susceptible</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Resistance/Partial Resistance</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With NNRTI Resistance During Follow-Up</title>
        <description>Characterization of baseline resistance and development of resistance using the interpretation system HIV-GRADE (available at www.hiv-grade.de. Genotypic interpretation was performed using the HIV-GRADE algorithm updated in December 2015). &quot;Susceptible&quot; indicates full susceptibility of a virus to a certain drug without any limitations in terms of resistance. &quot;Partial&quot; resistance is indicated if severe limitations in susceptibility have to be expected and the drug can not count for a fully active drug any more. However, these drugs can still be very useful in situations with generally limited options (salvage). &quot;Resistant&quot; indicates that high level drug resistance has to be expected.</description>
        <time_frame>up to Week 144</time_frame>
        <population>Participants with an assessment at follow-up; since this was an observational study, resistance testing was performed at the discretion of the treating physician.</population>
        <group_list>
          <group group_id="O1">
            <title>HIV-infected Participants</title>
            <description>HIV-infected participants on Kaletra and INIs or NNRTIs or CCR5 antagonists</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With NNRTI Resistance During Follow-Up</title>
          <description>Characterization of baseline resistance and development of resistance using the interpretation system HIV-GRADE (available at www.hiv-grade.de. Genotypic interpretation was performed using the HIV-GRADE algorithm updated in December 2015). &quot;Susceptible&quot; indicates full susceptibility of a virus to a certain drug without any limitations in terms of resistance. &quot;Partial&quot; resistance is indicated if severe limitations in susceptibility have to be expected and the drug can not count for a fully active drug any more. However, these drugs can still be very useful in situations with generally limited options (salvage). &quot;Resistant&quot; indicates that high level drug resistance has to be expected.</description>
          <population>Participants with an assessment at follow-up; since this was an observational study, resistance testing was performed at the discretion of the treating physician.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Susceptible</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Resistance/Partial Resistance</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Nucleoside Analog Reverse-Transcriptase Inhibitor (NRTI) Resistance at Baseline</title>
        <description>Characterization of baseline resistance and development of resistance using the interpretation system HIV-GRADE (available at www.hiv-grade.de. Genotypic interpretation was performed using the HIV-GRADE algorithm updated in December 2015). &quot;Susceptible&quot; indicates full susceptibility of a virus to a certain drug without any limitations in terms of resistance. &quot;Partial&quot; resistance is indicated if severe limitations in susceptibility have to be expected and the drug can not count for a fully active drug any more. However, these drugs can still be very useful in situations with generally limited options (salvage). &quot;Resistant&quot; indicates that high level drug resistance has to be expected.</description>
        <time_frame>Baseline (Week 0)</time_frame>
        <population>Participants with an assessment at Baseline</population>
        <group_list>
          <group group_id="O1">
            <title>HIV-infected Participants</title>
            <description>HIV-infected participants on Kaletra and INIs or NNRTIs or CCR5 antagonists</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Nucleoside Analog Reverse-Transcriptase Inhibitor (NRTI) Resistance at Baseline</title>
          <description>Characterization of baseline resistance and development of resistance using the interpretation system HIV-GRADE (available at www.hiv-grade.de. Genotypic interpretation was performed using the HIV-GRADE algorithm updated in December 2015). &quot;Susceptible&quot; indicates full susceptibility of a virus to a certain drug without any limitations in terms of resistance. &quot;Partial&quot; resistance is indicated if severe limitations in susceptibility have to be expected and the drug can not count for a fully active drug any more. However, these drugs can still be very useful in situations with generally limited options (salvage). &quot;Resistant&quot; indicates that high level drug resistance has to be expected.</description>
          <population>Participants with an assessment at Baseline</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="159"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Susceptible</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Resistance/Partial Resistance</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With NRTI Resistance During Follow-Up</title>
        <description>Characterization of baseline resistance and development of resistance using the interpretation system HIV-GRADE (available at www.hiv-grade.de. Genotypic interpretation was performed using the HIV-GRADE algorithm updated in December 2015). &quot;Susceptible&quot; indicates full susceptibility of a virus to a certain drug without any limitations in terms of resistance. &quot;Partial&quot; resistance is indicated if severe limitations in susceptibility have to be expected and the drug can not count for a fully active drug any more. However, these drugs can still be very useful in situations with generally limited options (salvage). &quot;Resistant&quot; indicates that high level drug resistance has to be expected.</description>
        <time_frame>up to Week 144</time_frame>
        <population>Participants with an assessment at follow-up; since this was an observational study, resistance testing was performed at the discretion of the treating physician.</population>
        <group_list>
          <group group_id="O1">
            <title>HIV-infected Participants</title>
            <description>HIV-infected participants on Kaletra and INIs or NNRTIs or CCR5 antagonists</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With NRTI Resistance During Follow-Up</title>
          <description>Characterization of baseline resistance and development of resistance using the interpretation system HIV-GRADE (available at www.hiv-grade.de. Genotypic interpretation was performed using the HIV-GRADE algorithm updated in December 2015). &quot;Susceptible&quot; indicates full susceptibility of a virus to a certain drug without any limitations in terms of resistance. &quot;Partial&quot; resistance is indicated if severe limitations in susceptibility have to be expected and the drug can not count for a fully active drug any more. However, these drugs can still be very useful in situations with generally limited options (salvage). &quot;Resistant&quot; indicates that high level drug resistance has to be expected.</description>
          <population>Participants with an assessment at follow-up; since this was an observational study, resistance testing was performed at the discretion of the treating physician.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Susceptible</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Resistance/Partial Resistance</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With HIV-1 Coreceptor Tropism at Baseline</title>
        <description>Participants with CCR5 tropic virus, CXC motif chemokine receptor 4 (CRCX4) tropic virus, or dual/mixed tropic virus at Baseline.</description>
        <time_frame>Baseline (Week 0)</time_frame>
        <population>Participants with an assessment at Baseline</population>
        <group_list>
          <group group_id="O1">
            <title>HIV-infected Participants</title>
            <description>HIV-infected participants on Kaletra and INIs or NNRTIs or CCR5 antagonists</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With HIV-1 Coreceptor Tropism at Baseline</title>
          <description>Participants with CCR5 tropic virus, CXC motif chemokine receptor 4 (CRCX4) tropic virus, or dual/mixed tropic virus at Baseline.</description>
          <population>Participants with an assessment at Baseline</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CCR5 tropic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CRCX4 tropic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dual/mixed tropic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With HIV-1 Coreceptor Tropism During Follow-up</title>
        <description>Participants with CCR5 tropic virus, CXC motif chemokine receptor 4 (CRCX4) tropic virus, or dual/mixed tropic virus at Follow-up.</description>
        <time_frame>up to Week 144</time_frame>
        <population>Since this was an observational study, resistance testing was performed at the discretion of the treating physician. No follow-up data on tropism was collected.</population>
        <group_list>
          <group group_id="O1">
            <title>HIV-infected Participants</title>
            <description>HIV-infected participants on Kaletra and INIs or NNRTIs or CCR5 antagonists</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With HIV-1 Coreceptor Tropism During Follow-up</title>
          <description>Participants with CCR5 tropic virus, CXC motif chemokine receptor 4 (CRCX4) tropic virus, or dual/mixed tropic virus at Follow-up.</description>
          <population>Since this was an observational study, resistance testing was performed at the discretion of the treating physician. No follow-up data on tropism was collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change From Baseline in HIV-1 Ribonucleic Acid (RNA) Viral Load</title>
        <description>Changes in participants' HIV-1 RNA viral load were assessed by measuring the change from Baseline at scheduled visits planned as part of routine care.</description>
        <time_frame>Baseline (Week 0) to Week 144</time_frame>
        <population>Participants with an assessment at Baseline. Number analyzed=participants with an assessment at given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>HIV-infected Participants</title>
            <description>HIV-infected participants on Kaletra and integrase inhibitors or non nucleoside reverse transcriptase inhibitors or CCR5 antagonists</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in HIV-1 Ribonucleic Acid (RNA) Viral Load</title>
          <description>Changes in participants' HIV-1 RNA viral load were assessed by measuring the change from Baseline at scheduled visits planned as part of routine care.</description>
          <population>Participants with an assessment at Baseline. Number analyzed=participants with an assessment at given time point.</population>
          <units>log copies/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="500"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="389"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.37" spread="1.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="408"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.53" spread="1.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="413"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.45" spread="1.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="367"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.49" spread="1.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="347"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.46" spread="1.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="320"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.27" spread="1.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 72</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="304"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.32" spread="1.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 84</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="269"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.34" spread="1.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 96</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="265"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.36" spread="1.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 108</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="233"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.32" spread="1.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 120</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="225"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.29" spread="1.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 132</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="213"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.33" spread="1.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 144</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="216"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.38" spread="1.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Time to Virologic Failure</title>
        <description>Time to virologic failure was defined by the earliest occurrence of:
HIV-1 RNA &gt; 400 copies/mL confirmed on 2 consecutive occasions after achieving at least 1 HIV-1 RNA &lt; 50 copies/mL,
HIV-1 RNA &gt; 400 copies/mL at the final on-study visit if the participant had previously experienced at least 1 HIV-1 RNA &lt; 50 copies/mL but subsequently did not have HIV-1 RNA &gt; 400 copies/mL on 2 consecutive occasions, or
Day 1 if the participant never achieved HIV-1 RNA &lt; 50 copies/mL during study participation.
A participant who prematurely discontinued study drug with HIV-1 RNA &lt; 50 copies/mL was censored from analysis at the time of discontinuation provided that he/she did not previously experience either (a), (b) or (c).</description>
        <time_frame>Baseline (Week 0) to Week 144</time_frame>
        <population>Participants with an assessment</population>
        <group_list>
          <group group_id="O1">
            <title>HIV-infected Participants</title>
            <description>HIV-infected participants on Kaletra and integrase inhibitors or non nucleoside reverse transcriptase inhibitors or CCR5 antagonists</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Virologic Failure</title>
          <description>Time to virologic failure was defined by the earliest occurrence of:
HIV-1 RNA &gt; 400 copies/mL confirmed on 2 consecutive occasions after achieving at least 1 HIV-1 RNA &lt; 50 copies/mL,
HIV-1 RNA &gt; 400 copies/mL at the final on-study visit if the participant had previously experienced at least 1 HIV-1 RNA &lt; 50 copies/mL but subsequently did not have HIV-1 RNA &gt; 400 copies/mL on 2 consecutive occasions, or
Day 1 if the participant never achieved HIV-1 RNA &lt; 50 copies/mL during study participation.
A participant who prematurely discontinued study drug with HIV-1 RNA &lt; 50 copies/mL was censored from analysis at the time of discontinuation provided that he/she did not previously experience either (a), (b) or (c).</description>
          <population>Participants with an assessment</population>
          <units>weeks</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="499"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="194.4" spread="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to Week 144</time_frame>
      <desc>Serious adverse events only were collected and coded by MedDRA. Per protocol, the number of participants with events were collected for each event, but from the source documentation to tell how many of the participants are counted in more than one adverse event (i.e., it is not possible to compute the Total Number of Participants Affected). Please see Outcome Measures 1 and 2 for these data.</desc>
      <group_list>
        <group group_id="E1">
          <title>HIV-infected Participants</title>
          <description>HIV-infected participants on Kaletra and integrase inhibitors or non nucleoside reverse transcriptase inhibitors or CCR5 antagonists</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 18.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="501"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>LYMPHADENOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>NEUTROPENIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>CARDIAC FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>STOMATITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>ASTHENIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>MULTI-ORGAN FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>OEDEMA PERIPHERAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERBILIRUBINAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>AIDS DEMENTIA COMPLEX</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>ACUTE HEPATITIS C</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>ANAL ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>CHLAMYDIAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>CYTOMEGALOVIRUS INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>INJECTION SITE ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>LYMPHOGRANULOMA VENEREUM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>PNEUMOCOCCAL SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>PNEUMONIA FUNGAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>SEPTIC SHOCK</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>SUBCUTANEOUS ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>TUBERCULOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>YERSINIA INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>FALL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>RADIUS FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ACTINOMYCES TEST POSITIVE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>ALANINE AMINOTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>ASPARTATE AMINOTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>GAMMA-GLUTAMYLTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>INFLAMMATORY MARKER INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>STREPTOCOCCUS TEST POSITIVE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>TROPONIN INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DEHYDRATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>DIABETES MELLITUS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>HYPERGLYCAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>HYPONATRAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>METABOLIC DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>FASCIITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>FISTULA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>INTERVERTEBRAL DISC PROTRUSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>BASAL CELL CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>BUSCHKE-LOWENSTEIN'S TUMOUR</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>KAPOSI'S SARCOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>NEUROENDOCRINE CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>PANCREATIC NEOPLASM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>ALTERED STATE OF CONSCIOUSNESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>CAROTID ARTERY ANEURYSM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>CAROTID ARTERY STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>CAROTID ARTERY THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>CEREBROVASCULAR ACCIDENT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>DEMENTIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>NERVOUS SYSTEM DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>SEIZURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>SYNCOPE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>TRANSIENT ISCHAEMIC ATTACK</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>VERTEBRAL ARTERY STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>WHITE MATTER LESION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE PSYCHOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>DELUSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>DEPRESSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>CHRONIC OBSTRUCTIVE PULMONARY DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>DYSPNOEA EXERTIONAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>INTERSTITIAL LUNG DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>PULMONARY OEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>SPUTUM DISCOLOURED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>DECUBITUS ULCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>LIPODYSTROPHY ACQUIRED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>ARTERIAL STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>ARTERIOSCLEROSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>CIRCULATORY COLLAPSE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>DEEP VEIN THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
              </event>
              <event>
                <sub_title>HYPERTENSIVE CRISIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Global Medical Services</name_or_title>
      <organization>AbbVie (prior sponsor Abbott)</organization>
      <phone>800-633-9110</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

